SAN DIEGO, Oct. 16, 2017 /PRNewswire/ Prometheus Laboratories Inc. announces a new therapeutic drug monitoring test for use in
adult inflammatory bowel disease (IBD) patients treated with Stelara®* (ustekinumab). PROMETHEUS
® Anser® UST enables
physicians to monitor this biologic therapy and optimize treatment. Careful monitoring of drug and antidrug antibodies is considered key
to optimizing biologic therapy in order to meet the emerging goals of personalized medicine. In clinical practice, measuring drug and
antidrug antibody concentrations has already proven effective in adapting treatment strategies in a variety of situations. As a drugtolerant
test, Anser® UST measures both serum drug concentrations and antidrug antibody levels from a single serum sample.
"Anser UST joins our expanding portfolio of drugtolerant therapeutic monitoring tests that help healthcare providers make optimal
treatment decisions," said Warren Cresswell, General Manager and Head of Diagnostics at Prometheus Laboratories Inc. "The addition
of Anser UST to our GI specialty test portfolio represents the continued commitment to innovation and better patient care that is
associated with all Prometheus diagnostics. The Anser portfolio of therapeutic drug monitoring tests now includes tests for infliximab
(and its biosimilars), adalimumab, vedolizumab, and ustekinumab."
"The availability of a drugtolerant assay such as Anser UST represents an important advancement in managing patients with Crohn's
disease," said William J. Sandborn, M.D., Chief, Division of Gastroenterology and Professor of Medicine, University of California San
Diego School of Medicine and Study Investigator. "Crohn's disease is a complex condition and optimizing the available therapies is an
important part of treatment."
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical
and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the
principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is expanding product development to
oncology testing. The company complements its proprietary diagnostic testing services with therapeutic products. By integrating
therapeutics and diagnostics, Prometheus provides physicians with more targeted solutions to optimize care for their patients.
Prometheus became part of Nestlé Health Science in 2011. For more information about Prometheus, please visit
About Nestlé Health Science
Nestlé Health Science, a whollyowned subsidiary of Nestlé, is a healthscience company engaged in advancing the role of nutritional
therapy to change the course of health for consumers, patients, and its partners in healthcare. Nestlé Health Science's portfolio of
nutrition solutions, diagnostics, devices, and drugs targets a number of health areas, such as inborn errors of metabolism, pediatric and
acute care, obesity care, healthy aging, and gastrointestinal and brain health. Through investing in innovation and leveraging leadingedge
science, Nestlé Health Science brings forward innovative nutritional therapies with clinical, health economic value, and quality of
life benefits. Nestlé Health Science employs around 3,000 people worldwide and is headquartered in Epalinges (near Lausanne),
Switzerland. For more information, please visit: www.nestlehealthscience.com.
PROMETHEUS, the Link Design, For the person in every patient, and Monitr are trademarks or registered trademarks of Société des
Produits Nestlé S.A. Vevey, Switzerland.
Contact for the media:
Geri VenaShores, Head of Marketing